Riociguat shows remarkable safety but underwhelming activity in patients with sickle cell disease

Lancet Haematol. 2024 May;11(5):e313-e314. doi: 10.1016/S2352-3026(24)00079-6. Epub 2024 Mar 27.
No abstract available

Publication types

  • News

MeSH terms

  • Anemia, Sickle Cell* / drug therapy
  • Humans
  • Pyrazoles* / adverse effects
  • Pyrazoles* / pharmacology
  • Pyrazoles* / therapeutic use
  • Pyrimidines* / adverse effects
  • Pyrimidines* / therapeutic use

Substances

  • Pyrazoles
  • Pyrimidines
  • riociguat